Risperdal, an atypical, antipsychotic drug, causes prolactin levels to increase at a much higher rate than similar medications. This increase in prolactin levels causes abnormal breast growth, a condition medically known as gynecomastia. From close to the time it was introduced to market in 1992, Janssen Pharmaceutical, Inc., and Johnson & Johnson hid this serious risk from doctors and the public in order to gain market share and increase sales, especially in the child/adolescent population, much of which was off-label promotion.
The warning label that was ultimately approved and published for Risperdal from 1992 until October 2006, basically remained the same with respect to prolactin and gynecomastia warnings. However, in internal documents published prior to 2006, Janssen admitted that Risperdal elevated prolactin more than other drugs in its class and even more in children. Janssen was promoting the drug off-label for use in children for a variety of maladies at the time. In the year 2000, the pediatric market accounted for 20 percent of Risperdal sales. In October 2006, the FDA approved Risperdal for use in children but only for treatment of irritability associated with autistic disorder.
The Litigation Group will help coordinate litigation strategy in actions involving cases against Ortho-McNeil-Janssen Pharmaceuticals, Inc., f/k/a Janssen Pharmaceutica, Inc., Johnson & Johnson Company, Johnson & Johnson Pharmaceutical Research and Development, and/or other entities relating to the off-label marketing of Risperdal (Risperidone) to the public, including children.
This Litigation Group was formed in February 2014.
The Risperdal Litigation Group has a list server and a document library where members can share information, documents, and pertinent information as well as holds education programs.
AAJ Annual and Winter Conventions, or as needed by group members.